Current treatments, such as estrogen receptor antagonists and mTOR inhibitors, have not yet proven consistently effective in mitigating pregnancy-related complications in LAM, underscoring the need for targeted therapies addressing the unique hormonal milieu of pregnancy [30]. Here, ESR1 is linked to lymphangioleiomyomatosis.